Insights into mechanisms of cisplatin resistance and potential for its clinical reversal

Pharmacotherapy

Volumn 16, Issue 1 I, 1996, Pages 16-39

  Gosland, Michael ^b   Lum, Bert ^b   Schimmelpfennig, Julia ^b   Baker, James ^b   Doukas, Michael ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; CALCIUM CHANNEL BLOCKING AGENT; CISPLATIN; CYCLOSPORIN; ETACRYNIC ACID; HYDROXYUREA; NOVOBIOCIN; PENTOXIFYLLINE; PLATINUM DERIVATIVE; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DNA REPAIR; DRUG MECHANISM; GERM CELL TUMOR; HUMAN; LUNG SMALL CELL CANCER; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CISPLATIN; DNA REPAIR; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; HYPERTHERMIA, INDUCED; METALLOTHIONEIN; SIGNAL TRANSDUCTION;

EID: 0030064573     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (200)

1. Rosenberg B. Fundamental studies with cisplatin. Cancer 1985,55.2303-16.
2. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990,2:35-43.
3. Scanlon KJ, Kashani-Sabet M, Tone T, Funato T. Cisplatin resistance in human cancers Pharmacol Ther 1991;52:385-406.
4. +-adenosine triphosphatase in the accumulation of cis-diammine-dichloroplatinum (II) in human ovarian carcinoma cells. Cancer Res 1991;51:3677-81.
5. Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin. a review Br J Cancer 1993,67:1171-6.
6. Kawai K, Kamatani N, Georges E, Ling V. Identification of a membrane glycoprotein overexpressed in murine lymphoma sublines resistant to cis-diamminedichloroplatinum (II). J Biol Chem 1990;265 13137-42.
7. Mistry P, Kelland LR, Loh SU, Abel G, Murrer B, Harrap K. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian cancer cell lines. Cancer Res 1992;52:6188-93.
8. Mann SC, Andrews PA, Howell SB. Short-term cis-diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian cancer cell lines. Cancer Chemother Pharmacol 1990;25:236-40.
9. Shionoya S, Lu Y, Scanlon KJ. Properties of amino acid transport systems in K562 cells sensitive and resistant to cis-diamminedichloroplatinum (II). Cancer Res 1986;46:3445-8
10. Hahn GM. Potential therapy of drugs and hyperthermia. Cancer Res 1979;39:2264-8
11. Wallner KE, Degregorio MW, Li GC. Hyperthermic potentiation of cis-diamminedichloroplatinum(II) cytotoxicity in Chinese hamster ovary cell lines resistant to the drug. Cancer Res 1986;46:6242-5.
12. Mansouri A, Henle KJ, Benson AM, Moss AJ, Nagle WA. Characterization of a cisplatin-resistant subline of murine RIF-1 cells and reversal of drug resistance by hyperthermia. Cancer Res 1989;49:2674-8.
13. Barlogie B, Corry PM, Drewinko B. In vitro thermotherapy of human colon cancer cells with cis-diamminedichloroplatinum (II) and mitomycin-C. Cancer Res 1980;40:1165-8.
14. Ohno S, Strebel FR, Stephens LC, et al. Haematological toxicity of carboplatin and cisplatin combined with whole body hyperthermia in rats. Br J Cancer 1993;68:469-74.
15. Los G, Sminia P, Wondergem J, et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. Eur J Cancer 1991,27:472-7.
16. Fletcher WS, Woltering EA, Moseley S, et al. Hyperthennic isolation limb perfusion (HILP) in the management of extremity melanoma and sarcoma with particular reference to the dosage, pharmacokinetics, and toxicity of cisplatin. In: Humphrey GB, ed. Osteosarcoma in adolescents and young adults. New York: Academic Press, 1993 241-4
17. Sayag AC, Gilly FN, Carry PY, et al. Intraoperative chemohyperthermia in the management of digestive cancers: a general review of the literature. Oncology 1993;50:333-7.
18. Gilly FN, Carry PY, Brachet A, et al. Treatment of malignant peritoneal effusion in digestive and ovarian cancers. Med Oncol Tumor Pharmacother 1992;9:177-81.
19. Takeyama S, Tateishi A, Higaki S, Yamanashi M. Hyperthermic isolated perfusion using cisplatin for the treatment of the extremities In: Humphrey GB, ed. Osteosarcoma in adolescents and young adults. New York: Academic Press, 1993:235-40.
20. Mann SC, Andrews PA, Howell SB. Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer 1991;48:866-72.
21. Morikage T, Ohmori T, Nishio K, Fujiwara Y, Takeda Y, Saijo N. Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines. Cancer Res 1993;53.3302-7.
22. Silvestrini R, Zaffaroni N, Villa R, Orlandi L, Costa A. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int J Cancer 1992;52 813-17
23. Schmoll HJ, Harstrick A, Kohne-Wompner CH, Schober C, Wilke H, Poliwoda H. Modulation of cytotoxic drug activity by dipyridamole. Cancer Treat Rev 1990,17:57-65.
24. Floridi A, Paggi MG, Marcante ML Silvestrini B, Caputo A, De Martino C. Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. J Natl Cancer Inst 1981;66:497-9.
25. Ko D, Raaphorst P, Feely MH, Danjoux CE, Maroun JA, Evans WK. The in vitro effects of lonidamine combined with cisplatin in human small cell lung cancer cell lines. Anticancer Res 1991,11:235-40.
26. Hahn GM, van Kersen I, Silvestrini B. Inhibition of the recovery from potentially lethal damage by lonidamine. Br J Cancer 1984;50:657-60.
27. Teicher BA, Holden SA, Herman TS, Frei E. Modulation of alkylating agents by lonidamine in vivo. Semin Oncol 1991;18(2 suppl 4):7-10.
28. Robustelli della Cuna G, Pedrazzoli P. Toxicity and clinical tolerance of lonidamine. Semin Oncol 1991,18 18-22.
29. Howell SB, Vick J, Andrews PA, Velury S, Sanga R. Biomedical modulation of cisplatin. Dev Oncol 1988;54:228-34.
30. Keane TE, Rosner GL, Gingrich JR, Poulton SHM, Walther PJ. The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/ cisplatin in an animal model of human bladder cancer J Urol 1991;146:1418-24.
31. Meister A. Glutathione metabolism and its selective modification. J Biol Chem 1988,263.17205-8.
32. Arrick BA, Nathan CF. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res 1984;44:4224-32.
33. Mistry P, Harrap KR. Historical aspects of glutathione and cancer chemotherapy Pharmacol Ther 1991,49:125-32.
34. Fram RJ, Woda BA, Wilson JM, Robichaud N. Characterization of acquired resistance to cis-diamminedichloroplatinum (ii) in BE human colon carcinoma cells. Cancer Res 1990;50:72-7.
35. Hamilton TC, Winker MA, Kouie KG, et al. Augmentation of Adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine-mediated glutathione depletion Biochem Pharmacol 1985;34:2583-6
36. Hospers GAP, Mulder NH, De Jong B, et al. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res 1988,48:6803-7.
37. Meijer C, Mulder NH, Hospers GAP, Uges DRA, De Vries EG The role of gluiathione in resistance to cisplatin in a human small cell lung cancer cell line Br J Cancer 1990;62:72-7.
38. Meijer C, Mulder NH, de Vries EG. The role of detoxifying systems in resistance of tumor cells to cisplatin and Adriamycin. Cancer Treat Rev 1990;17:389-407.
39. Teichner BA, Holden SA, Kelley MJ, et al. Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum (ii). Cancer Res 1987,47:388-93
40. Hospers GA, Meijer C, de Leij L, Uges DR, Mulder NH, de Vries EG A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance Int J Cancer 1990;46 138-44
41. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis Proc Natl Acad Sci USA 1992;89:3070-4.
42. Hrubisko M, McGown AT, Fox BW. The role of metallothionein, glutathione, glutathione S-transferases, and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents Biochem Pharmacol 1993,45:253-6
43. Wang Y, Teichner B, Shea T, et al. Cross-resistance and glutathione S-transferase-π levels among four human melanoma cell lines selected for alkylating agent resistance Cancer Res 1989;49:6185-92.
44. Saburi Y, Nakagawa M, Ono M, et al. Increased expression of glutathione S-transferase gene in cis-diammmedichloroplatinum(ii)-resistant variants of a Chinese hamster ovary cell line Cancer Res 1989;49.7020-5.
45. Nakagawa K, Saijo N, Tsuchida S, et al. Glutathione S-transferase π as a determinant of drug resistance in transfectant cell lines. J Biol Chem 1990,265:4296-4301.
46. Waxman DJ. Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation of chemotherapy - a review. Cancer Res 1990,50:6449-54.
47. Pickett CB, Lu AYH. Glutathione S-transferases: gene structure, regulation, and biological function. Annu Rev Biochem 1989;58:743-64
48. Yao K, Godwin A, Ozols R, Hamilton T, O'Dwyer P. Variable baseline γ-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. Cancer Res 1993;53 3662-6.
49. Hayes J, Kerr L, Crownshaw A. Evidence that glutathione S-transferase B1B1 and B2B2 are products of separate genes and that their expression in human liver is subject to interindividual variations Biochem J 1989;264.437-45.
50. Moscow J, Fairchild C, Madden M, et al. Expression of anionic glutathione S-transferase and p-glycoprotein genes in human tissues and tumors Cancer Res 1989,49:1422-8
51. Howie A, Forrester LM, Glancey MJ, et al. Glutathione S-transferase and glutathione peroxidase expression in normal and tumour human tissues Carcinogenesis 1990;11:451-8.
52. Perry R, Mazetta J, Levin M, Barranco S. Glutathione levels and variability in breast tumors and normal tissues. Cancer 1993;72.783-7
53. Lee F, Vessey A, Rofstad E, Siemann D, Sutherland R. Heterogeneity of glutathione content in human ovarian cancer Cancer Res 1989;49:5244-8.
54. Ogawa J, Iwazaki M, Inoue H, Koide S, Shotsu A. Immunohistochemical study of glutathione-related enzymes and proliferation antigens in lung cancer. Cancer 1993,71:2204-9.
55. Gilbert L, Elwood LJ, Merino M, et al. A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol 1993;11:49-58.
56. Raganathan S, Tew KD. Analysis of glyoxalase-I from normal and tumor tissue from human colon. Biochim Biophys Acta 1993,1182:311-16
57. Efferth T, Mattern J, Volm M. Immunohistochemical detection of p-glycoprotein, glutathione S-transferase and DNA topoisomerase II in human tumors. Oncology 1992;49:36-7.
58. Toffoli G, Frustaci S, Tumiotto L, et al. Expression of MDR1 and GST-π in human soft tissue sarcomas: relation to drug resistance and biological aggressiveness. Ann Oncol 1992;3.63-9.
59. Hanada K, Ishikawa H, Tamai K, Hashimoto I, Sato K. Expression of glutathione S-transferase-pi in malignant skin tumors. J Dermatol Sci 1991;2:18-23
60. Ishioka C, Kanamaru R, Shibata H, et al. Expression of glutathione S-transferase-pi messenger RNA in human esophageal cancers. Cancer 1991,67:2560-4.
61. Bourhism J, Hartmann O, DeVathaire F, et al. Expression of MDR1 and GST pi genes in 35 advanced neuroblastomas. Prog Clin Biol Res 1991;366 127-34.
62. Holmes J, Wareing C, Jacobs A, Hayes JD, Padua RA, Wolf C. Glutathione S-transferase pi expression in leukaemia, a comparative analysis with mdr-1 data. Br J Cancer 1990;62:209-12
63. Hromas RA, Andrews PA, Murphy MP, Burns CP. Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells Cancer Lett 1987;34:9-13
64. Lai GM, Ozols RF, Young RC, Hamilton TC. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. J Natl Cancer Inst 1989;81:535-9.
65. Ozols RF, Louie KG, Plowman J, et al. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. Biochem Pharmacol 1987,36:147-53.
66. Saikawa Y, Kubota T, Kuo T, et al. Enhancement of antitumor activity of cisplatin in human gastric cancer cells in vitro and in vivo by buthionine sulfoximine. Jpn J Cancer Res 1993,84.787-93
67. Ahokas J, Davies C, Ravenscroft P, Emmerson B. Inhibition of soluble glutathione S-transferase by diuretic drugs. Biochem Pharmacol 1984;33:1929-32.
68. Ploemen JHTM, van Ommen B, van Bladeren PJ. Inhibition of rat and human glutathione S-transferase isoenzyme by ethacrynic acid and its glutathione conjugate Biochem Pharmacol 1990,40.1631-5.
69. Ploemen JHTM, van Ommen B, Bogaards J, van Bladeren J. Ethacrynic acid and its glutathione conjugate as inhibitors of glutathione-S-transferases. Xenobiotica 1993;23.913-23.
70. Hansson J, Berhane K, Castro VM, Jungnelius U, Mannervik B, Ringborg U. Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor ethacrynic acid. Cancer Res 1991;51 94-8.
71. Clapper M, Hoffman S, Tew K. Sensitization of human colon tumor xenografts to L-phenylalanine mustard using ethacrynic acid J Cell Pharmacol 1990;1:71-8
72. Rhodes T, Twentyman PA. A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines Br J Cancer 1992;65.684-90.
73. O'Dwyer P, Hamilton T, Young R, et al. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results J Natl Cancer Inst 1992,84:264-7.
74. Bailey H, Mulcahy T, Tutsch K, et al. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 1994;12.194-205.
75. O'Dwyer PJ, LaCreta F, Nash S, et al. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid Cancer Res 1991;51 6059-65.
76. Webb M, Chain K. Functions of metallothionein. Biochem Pharmacol 1982;31:137-42.
77. Hamer DH. Metallothionein. Annu Rev Biochem 1986;55:913-51
78. Bakka A, Endresen L, Johnsen ABS, Edminson PD, Rugstad HE. Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothionein. Toxicol Appl Pharmacol 1981;61:215-26
79. Andrews PA, Murphy MP, Howell SB. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells Cancer Chemother Pharmacol 1987;19:149-54.
80. Schilder RJ, Hall L, Monks A, et al. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Int J Cancer 1990;45:416-22.
81. Kelley SL, Basu A, Teichner BA, Hacker MP, Hamer DA, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs Science 1988;241:1813-15
82. Morton KA, Jones BJ, Sohn M, Datz FL, Lynch RR. Enrichment for metallothionem does not confer resistance to cisplatin in transfected NIH/3T3 cells J Pharmacol Ther 1993;267.697-702.
83. Basu A, Lazo JS. Suppression of dexamethasone-induced metallothionein expression and cis-diamminedichloroplatinum(II) resistance by v-mos. Cancer Res 1991,51:893-6.
84. Aapro MS, Alberts DS, Serokman R. Lack of dexamethasone effect on the antitumor activity of cisplatin Cancer Treat Rep 1983;67:1013-17.
85. Satoh M, Cherian GM, Imura N, Shimizu H. Modulation of resistance to anticancer drugs by inhibition of metallothionem synthesis Cancer Res 1994,54:5255-7.
86. Ducore JM, Erickson LC, Zwelling LA, Laurent G, Kohn KW. Comparative studies of DNA cross-linking and cytotoxicity in Burkitt's lymphoma cell lines treated with cis-diamminedichloroplatinum(II) and L-phenylalanine mustard. Cancer Res 1982,42:897-902.
87. Eastman A. Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry 1986;25:3912-15
88. Eastman A, Schulte N. Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(ii). Biochemistry 1988;27.4730-4
89. Micetich K, Zwelling LA, Kohn KW. Quenching of DNA-platinum(ii) monoadducts as a possible mechanism of resistance to cis-diamminedichloroplatinum(ii) in L1210 cells. Cancer Res 1983;43:3609-13
90. Venderik CPJ, Bergers JJ, de Jong WWH, Steerenberg PPA. Resistance to cytostatic drugs at the cellular level. Cancer Chemother Pharmacol 1992;29:413-29.
91. Dijt FJ, Fichtinger-Schepman AMJ, Berends F, Reedijk J. Formation and repair of cisplatin induced adducts to DNA in cultured normal and repair-deficient human fibroblasts Cancer Res 1988;48 6058-62.
92. Chu G, Chang E. Xeroderma pigmentosum group E cells lack a nuclear factor that binds to damaged DNA. Science 1998;24:564-7.
93. Chu G, Chang E. Cisplatin-resistant cells express increased levels of a factor that recognizes damaged DNA. Proc Natl Acad Sci USA 1990;87.3324-7.
94. Chu G. Cellular responses to cisplatin: the roles of DNA-binding proteins and DNA repair J Biol Chem 1994,269:787-90.
95. Dabholkar M, Bostick-Bruton F, Weber C, Bohr V, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992,84:1512-17.
96. Westerveld A, Hoeijmakers J, van Duin M, et al. Molecular cloning of a human DNA repair gene. Nature 1984;310:425-8.
97. Jones J, Zhen W, Reed E, Parker R, Sancar A, Bohr V. Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells J Biol Chem 1991;266.7101-7.
98. Bruhn SL, Pil PM, Essigmann JM. Isolation and characterization of human cDNA encoding a high mobility group box that recognizes structural distortions to DNA caused by binding of the antitumor agent cisplatin. Proc Natl Acad Sci USA 1992;89:2307-11.
99. Pil PM, Lippard SJ. Specific binding of chromosomal protein HMG1 to DNA damaged by the anticancer drug cisplatin Science 1992;256:234-7.
100. Billings PC, Davis RJ, Engelsberg BN. Characterization of high mobility group protein binding to cisplatin-damaged DNA Biochem Biophys Res Commun 1992;188:1286-94.
101. Kashani-Sabet M, Scanlon KJ. Drug selectivity and membrane transport properties of normal human lymphocytes Chemotherapy 1989;35:363-72.
102. Scanlon K, Newman E, Lu Y, Priest D. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells Proc Natl Acad Sci USA 1986,83:8923-5
103. Lai GM, Ozols RF, Smyth JF, Young RC, Hamilton TC. Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. Biochem Pharmacol 1988,37:4597-4600
104. Katz EJ, Andrews PA, Howell SB. The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells Cancer Commun 1990;2:159-64.
105. Masuda H., Ozols RF, Lai GM, Fojo A, Rothenberg MC, Hamilton TC. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res 1988, 48:5713-16.
106. Hanaoke F, Kato H, Ikegami S, Ohashi M, Yamada M. Aphidicolin does inhibit repair replication in HeLa cells Biochem Biophys Res Commun 1979,87:575-80.
107. Damia G, Tagliabue G, Zucchetti M, et al. Activity of aphidicolin glycinate alone or in combination with cisplatin in murine ovarian tumor resistant to cisplatin. Cancer Chemother Pharmacol 1992;30 459-64.
108. Sessa C, Zucchetti M, Davoli E, et al. Phase I and clinical pharmacological evaluation of aphidicolin glycmate. J Natl Cancer Inst 1991;83:1160-4.
109. Ozawa S, Sugiyama Y, Mitsuhashi J, Inaba M. Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells. Cancer Res 1989;49:3823-8.
110. Trujillo JM, Yang LY. Synergism of 1-β-D-arabinofuranosylcytosine and cis-diamminedichloroplatinum(II) in their lethal efficacies against seven established cancer cell lines of gastrointestinal origin. Anticancer Res 1989;9.197-202.
111. Berek J, Schink JC, Knox RM. Synergistic effect of combined intraperitoneal cisplatin and cytosine arabinoside in a murine ovarian cancer model Obstet Gynecol 1989;741:663-6.
112. Kern DH, Morgan CR, Hildebrand-Zanki S. In vitro pharmacodynamics of 1-β-D-arabinofuranosylcytosine: synergy of antitumor activity with cis-diamminedichloroplatinum(ii) Cancer Res 1988;48.117-21.
113. Howell SB, Gill S. Lack of synergy between cisplatin and cytarabine against ovarian carcinoma Cancer Treat Rep 1986;70:409-10.
114. Swinnen LJ, Barnes DM, Fisher SG, Albain KS, Fischer RI, Erickson LE. 1-β-D-arabinofuranosylcytosine and hydroxyurea production of cytotoxic synergy with cis-diammmedichloroplatinum(II) and modification of platinum-induced DNA interstrand cross-linking. Cancer Res 1989;49:1383-9.
115. Swinnen LJ, Ellis NK, Erickson LC. Inhibition of cis-diammine-1,1-cyclobutane dicarboxylatoplatinum(ii)-induced DNA interstrand cross-link removal and potentiation of cis-diammine-1,1-cyclobutanedicarboxylatoplatinum(II) cytotoxicity by hydroxyurea and 1-β-D-arabinofuranosylcytosine. Cancer Res 1991;51:1984-9.
116. Albain K, Swinnen LJ, Erickson L, Stiff PJ, Fisher R. Cisplatin proceeded by concurrent cylarabine and hydroxyurea: a pilot study based on an in vitro model. Cancer Chemother Pharmacol 1990,27:33-40
117. Timmer-Bosscha H, Muldher NH, de Vries EGE. Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer 1991;66:227-38.
118. Kyriazis AP, Kyriazis AA, Yogoda A. Enhanced therapeutic effect of cis-diamminedichloroplatinum(ii) resistant against nude mouse grown pancreatic adenocarcinoma when combined with 1-β-arabinofuranosylcytosine and caffeine. Cancer Res 1985,45:6083-7.
119. Schiano M, Sevin B, Perras J, Ramos R, Wolloch E, Averette H. In vitro enhancement of cis-platinum antitumor activity by caffeine and pentoxifylline in a human ovarian cell line. Gynecol Oncol 1991,43:37-45
120. Stewart D, Cripps MC, Fingert HH, Lamothe A, Laframboise G, Gerin-Lajoie J. Cisplatin, cytosine arabinoside, and pentoxifylline in the treatment of squamous cell carcinoma of the head and neck Am J Clin Oncol 1993,16.123-6.
121. Scanlon KJ, Kashni-Sabet M, Sowers LC. Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention of azidothymidine Cancer Commun 1989,1:269-75
122. Scanlon KJ, Kashni-Sabet M, Miyachi H, Sowers LC, Rossi JJ. Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. Anticancer Res 1989,9:1301-12.
123. Scanlon KJ, Funato T, Pezeshki B, Tone T, Sowers LC. Potentiation of azidothymidine cytotoxicity in cisplatin-resistant human ovarian carcinoma cells. Cancer Commun 1990;2:339-43.
124. Perez RP, Hamilton TC, Ozols RF. Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. Pharmacol Ther 1990;48.19-27.
125. Klann R, Holbrook T, Nyce J. Chemotherapy of murine colorectal carcinoma with cisplatin and cisplatin with 3″-deoxy-3′-azidothymidine. Anticancer Res 1992,12:781-8.
126. Schabel FM, Trader MW, Laster WR, Corbett TH, Griswold DP, Jr. Cis-dichlorodiammineplatinum(ii): combination chemotherapy and cross resistance studies with tumors in mice Cancer Treat Rep 1979,63:1459-73
127. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 1986,83:8923-5.
128. Newman EM, Lu Y, Kashni-Sabet M, Kesavan V, Scanlon KJ. Mechanisms of cross-resistance to methotrexate and 5-fluorouracil in an A2780 human ovarian carcinoma cell subline resistant to cisplatin. Biochem Pharmacol 1988;37:443-7.
129. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993;85:95-111
130. Evans WK, Osba D, Feld R, Shepard FA, Bazos MJ, DeBoer G. Etoposide and cisplatin: an effective treatment for relapse small-cell lung cancer. J Clin Oncol 1985;3:65-71.
131. Sculier JP, Klastersky J. Progress in chemotherapy of non-small cell lung cancer. Eur J Clin Oncol 1984;20:1329-33
132. Katz EJ, Vick JS, Kling KM, Andrews PA, Howell SB. Effect of topoisomerase modulators on cisplatin toxicity in human ovarian carcinoma cells Eur J Cancer 1990;26:724-7.
133. de Jong S, Timmer-Bosscha H, de Vries EGE, Mulder NH. Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link formation in a cisplatin-resistant small cell lung carcinoma cell line Int J Cancer 1993,53.110-17.
134. Ellis GK, Crowley J, Livingston RB, Goodwin JW, Hutchins L, Allen A. Cisplatin and novobiocin in the treatment of non-small cell lung cancer. A Southwest Oncology Group study. Cancer 1991;67:2969-73.
135. Burkle A, Chen G, Kupper JH, Grube K, Zeller WJ. Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment Carcinogenesis 1991;14 559-61.
136. Chen G, Zeller WJ. Multiple effects of 3-aminobenzamide on DNA damage induced by cisplatin (DDP) in DDP-sensttive and -resistant rat ovarian tumor cell lines. Cancer Lett 1992,67 27-33
137. Chen G, Pan Q. Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide. Cancer Chemother Pharmacol 1988;22:303-7.
138. Chen G, Zeller WJ. Enhancement of cisplatin (DDP) antitumor activity by 3-aminobenzamide in rat ovarian tumors sensitive and resistant to DDP in vivo. Cancer Chemother Pharmacol 1990;26.37-41.
139. Timmer-Bosscha H, Hospers GAP, Meijer C, et al. Influence of docosahexanoic acid on cisplatin resistance in human small cell lung carcinoma cell line J Natl Cancer Inst 1989,81:1069-75.
140. Awad AB, Spector AA. Modification of Ehrlich ascites tumor cell nuclear lipids. Biochim Biophys Acta 1976;450.239-51.
141. Isonishi S, Hom DK, Thiebaut FB, et al. Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res 1991;51:5903-9.
142. Schmidt C, Hamer DH. Cell specificity and an effect of ras on human metallothionein gene expression. Proc Nad Acad Sci USA 1986,83:3346-50.
143. Abate C, Luk D, Curran T. Transcriptional regulation by Fos and Jun in vitro: interaction among multiple activator and regulatory domains Mol Cell Biol 1991;11:3624-32
144. Buscher M, Rahmsdorf HJ, Litfin M, Karin M, Herrlich P. Activation of the c-fos gene by UV and phorbol ester: different signal transduction pathways coverage to the same enhance element. Oncogene 1988;3:301-11.
145. Lee W, Mitchell P, Tjian R. Purified transcription factor AP-1 interacts with TPA inducible enhancer elements Cell 1987;49:741-52.
146. Hollander MC, Fornace AJ, Jr. Induction of fos RNA by DNA-damaging agents. Cancer Res 1989;49.1687-92
147. Karolak L, Chandra A, Khan W, et al. High dose chemotherapy-induced platelet defect: inhibition of platelet signal transduction pathways Mol Pharmacol 1993;43:37-44.
148. Kashni-Sabet M, Lu Y, Leong L, Haedicke K, Scanlon KJ. Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil. Eur J Cancer 1990;26:383-90.
149. Niimi S, Nakagawa K, Yokota J, et al. Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or H-ras genes. Br J Cancer 1991;63:237-41
150. Sklar MD. Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res 1988;48:793-7.
151. Bravo R, Burckhardt J, Curran T, Muller R. Stimulation and inhibition of growth by EGF in different A431 cell clones is accompanied by the rapid induction of c-fos and c-myc protooncogenes. EMBO J 1985;4:1193-7.
152. Dassonville O, Formento J, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract Cancer. J Clin Oncol 1993;11:1873-8.
153. Nishikawa K, Rosenblum M, Newman R, Pandita T, Hittelman W, Donato N. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin; evidence of a role for DNA repair and epidermal growth factor receptor. Cancer Res 1992,52.4758-65.
154. Isonishi S, Andrews PA, Howell SB. Increased sensitivity to cis-diamminedichloroplatinum(ii) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem 1990,265: 3623-7.
155. Basu A, Teicher BA, Lazo JS. Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cisdiamminedichloroplatinum(II). J Biol Chem 1990,265: 8451-7.
156. Basu A, Kozikowki AP, Sato K, Lazo JS. Cellular sensitization to cis-diamminedichloroplatinum(II) by novel analogs of the protein kinase C activator lyngbyatoxin A Cancer Res 1991,51:2511-14
157. Hanauske AR, Degen D, Marshall MH, Hilsenbeck SG, McPhillips JJ, Von Hoff D. Preclinical activity of ilmofosine against human tumor colony forming units in vitro Anticancer Drugs 1992,3:43-6.
158. Hofmann J, Doppler W, Jakob A, et al. Enhancement of the antiproliferative effect of cis-diammmedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer 1988;42 382-8.
159. Scambia G, Ranetelli F, Benedetti Panici P, et al. Synergistic antiproliferative activity of quercetin and cis-diamminedichloroplatinum(II) on ovarian cancer cell growth. Anticancer Drugs 1990;1:45-8
160. McClay EF, Albright KD, Jones JJ, Eastman A, Christen R, Howell SB. Modulation of cisplatin resistance with human melanoma cells. Cancer Res 1992;52.6790-6
161. McClay EF, Albright KD, Jones JJ, Christen RO, Howell SB. Tamoxifen modulation of cisplatin cytotoxicity in human malignancies. Int J Cancer 1993,55 1018-22.
162. Kikuchi Y, Hirata J, Kita T, Imaizumi E, Tode T, Nagata I. Enhancement of antiproliferative effect of cis-diamminedichloroplatinum(ii) by clomiphene and tamoxifen in human ovarian cancer cells. Gynecol Oncol 1993;49.365-72.
163. McClay EF, Albright K, Jones J, Christen R, Howell SB. Tamoxifen modulation of cisplatin sensitivity in human malignant melanoma cells. Cancer Res 1993;53:1571-6.
164. McClay EF, McClay ME, Albright KD, et al. Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma. Cancer 1993,72:1914-18
165. McClay EF, Mastrangelo MJ, Sprandio JD, Bellet RE, Berd D. The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer 1989;63:1292-5.
166. Kashnani-Sabet M, Wang W, Scanlon KJ. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J Biol Chem 1990,265:11285-8.
167. Hong WS, Saijo N, Saski Y, et al. Establishment and characterization of cisplatin-resistant sublines of human lung cancer cells. Int J Cancer 1988;42:462-7.
168. Manetta A, Boyle J, Berman ML, et al. Cyclosporine enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer Cancer 1994;73:196-9.
169. Cohen DJ, Curran T. The structure and function of the fos proto-oncogene. Oncogenesis 1989;1:65-88.
170. Scanlon KJ, Jiao L, Funato T, et al. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein J Biol Chem 1991;88.10591-5.
171. Funato T, Yoshida E, Jiao L, Tone T, Kashni-Sabet M, Scanlon KJ. The utility of an antifos ribozyme in reversing cisplatin resistance in human carcinomas. Adv Enzyme Regul 1992;32:195-209.
172. Kashni-Sabet M, Funato T, Tone T, et al. Reversal of the malignant phenotype by an anti-Ras ribozyme Antisense Res Dev 1992;2:3-15.
173. Cole K, Kohn E. Calcium-mediated signal transduction-biology and therapy Cancer Metastasis Rev 1994;13 31-44
174. Onoda JM, Jacobs JR, Taylor JD, Sloane BF, Honn K. Cisplatin and nifedipine: synergistic cytotoxicity against murine solid tumors and their metastasis. Cancer Lett 1986,30:181-6.
175. Onoda JM, Nelson KK, Taylor JP, Honn KV. In vitro characterization of the combination antitumor chemotherapy with calcium blockers and cis-diamminedichloroplatinum(II). Cancer Res 1989;49:2844-50
176. Charp PA, Regan JD. Inhibition of DNA repair by trifluoperazine Biochim Biophys Acta 1985;824:34-9.
177. Christian MC. The current status of new platinum analogs. Semin Oncol 1992;19:720-33.
178. Weiss RB, Christian MC. New cisplatin analogs in development. A review. Drugs 1993;46:360-77.
179. Schmidt W, Chaney SG. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res 1993;53:799-805.
180. Anderson WK, Quagliato DA, Haugwitz RD, Narayanan V, Wolpert-Defilipes M. Synthesis, physical properties, and antitumor activity of tetraplatin and related tetrachloroplatinum (IV) stereoisomers of 1,2-diaminocyclohexane Cancer Treat Rep 1986;70:997-1002.
181. Harrap KR, Jones M, Siracky J, Pollard L, Kelland L. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs. Ann Oncol 1990;1:65-76.
182. O'Rouke T, Rodriquez G, Eckardt J, et al. Neurotoxicity of ormaplatin (NSC 363812) in a phase I trial of a daily times five schedule [abstr]. Proc Am Soc Clin Oncol 1993;12.137.
183. Christian M, Kohn E, Sarosy G, et al. Phase I and pharmacologic study of ormaplatin (OP)/tetraplatin [abstr] Proc Am Soc Clin Oncol 1992;11:117
184. Mathe G, Kidani Y, Noji M, Moral R, Bourut C, Chenu E. Antitumor activity of L-OHP in mice. Cancer Lett 1985;27:135-43.
185. Silvestro L, Anal H, Sommer F, Trical G, Talpero H. Comparative effects on a new platinum analog (trans-1-diamine-cyclohexane oxalato-platinum, L-OHP) with CDDP on various cells; correlation with intracellular accumulation Anticancer Res 1990;10:1376
186. Tashiro T, Kawada Y, Sakurai Y, Kidani Y. Antitumor activity of a new platinum complex, oxalato (trans-L-1,2-diammocyclohexane) platinum (ii); new experimental data Biomed Pharmacother 1989;43:251-60.
187. Extra J, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer Cancer Chemother Pharmacol 1989,25:299-303.
188. Caussanel JP, Levi F, Brienza S, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990;82:1046-50.
189. Durr F, Carvajak S, Wallace R. Two new platinum complexes with significant antitumor activity in mice [abstr] Proceedings of the 6th NCI-EORTC symposium on new drugs in cancer therapy. Amsterdam, 1989 198
190. Kelland LR. New platinum antitumor complexes. Crit Rev Oncol Hematol 1993;15:191-219.
191. Willemse PHB, Gietema JA, Mulder NH, et al. Zeniplatin in patients with advanced ovarian cancer, a phase II study with a third generation platinum complex. Eur J Cancer 1993;29A.359-62.
192. Jones AL, Smith IE. Zeniplatin, an active new platinum analog in advanced non-small cell lung cancer (NSCLC): a phase II study [abstr]. Proc Am Soc Clin Oncol 1991;10:268.
193. Olver I, Green M, Peters W, et al. A phase II trial of zeniplatin in metastatic melanoma Am J Clin Oncol 1995;18:56-8.
194. Kudelka A, Edwards C, Freedman R, et al. Phase II study of enoplatin for patients (pts) with advanced ovarian cancer [abstr]. Proc Am Soc Clin Oncol 1993;12:269.
195. Harstrick A, Bokemeyer C, Scharnofkse M, Hapke G, Reile D, Schmoll H. Preclinical activity of a new platinum analog, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines Cancer Chemother Pharmacol 1993;33:43-7.
196. Kavanaugh JJ, Edwards CL, Freddman RS, et al. A trial of lobaplatin (D-19466) in platinum resistant ovarian cancer Gyn Oncol 1995;58(1):106-9.
197. Khokhar A, Al-Baker S, Krakoff I, Perez-Soler R. Toxicity and antitumor activity of cis-bis-carboxylato-(trans-R,R-1,2-diamminocyclohexane platinum(ii) complexes entrapped in liposomes. Cancer Chemother Pharmacol 1989;23:2219-23.
198. Perez-Soler R, Lopez-Berestein G, Lautersztain J, et al. A phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II). Cancer Res 1990;50:4254-9.
199. Farrell N. Nonclassical platinum antitumor agents: perspectives for design and development of new drugs complementary to cisplatin. Cancer Invest 1993;11:578-89.
200. Van Beusichem M, Farrell N. Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterization and biological activity of complexes with planar ligands pyridme, N-methylimidazole, thiazole and quinolone The crystal and molecular structure of trans-dichlorobis(thiazole)platinum(II). Inorg Chem 1992;31: 634-9.